Trospium
Active ingredient: Trospium Chloride
In short: Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
What is Trospium used for?
Trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Trospium dosage
The recommended dose is 20 mg twice daily. Trospium chloride tablets should be dosed at least one hour before meals or given on an empty stomach.
Dosage modification is recommended in the following patient populations:
For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the recommended dose is 20 mg once daily at bedtime [
see
Warnings and Precautions (5.5),
Use in Specific Populations (8.6), and
Clinical Pharmacology (12.3)
].
In geriatric patients greater than or equal to 75 years of age, dose may be titrated down to 20 mg once daily based upon tolerability .
How to take Trospium — instructions & advice from the label
“See FDA-approved Patient Labeling (Patient Information)”
Patients should be informed that trospium chloride, the active ingredient in trospium chloride tablets, may produce angioedema which could result in life-threatening airway obstruction. Patients should be advised to promptly discontinue trospium chloride tablets and seek immediate medical attention if they experience edema of the tongue, edema of the laryngopharynx, or difficulty breathing.
Prior to treatment, patients should fully understand the risks and benefits of trospium chloride tablets. In particular, patients should be informed not to take trospium chloride tablets if they:
have urinary retention;
gastric retention;
uncontrolled narrow-angle glaucoma;
are allergic to any component of trospium chloride tablets.
Patients should be instructed regarding the recommended dosing and administration of trospium chloride tablets:
Take one trospium chloride tablet twice daily with water.
Take trospium chloride tablets on an empty stomach or at least 1 hour before a meal. …
Warnings & precautions
Do not take this medicine if: Trospium chloride is contraindicated in patients with:
urinary retention
gastric retention
uncontrolled narrow-angle glaucoma.
known hypersensitivity to the drug or its ingredients. Angioedema, rash and anaphylactic reaction have been reported.
Trospium chloride should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention .
Angioedema of the face, lips, tongue, and/or larynx has been reported with trospium chloride, the active ingredient in trospium chloride. In one case, angioedema occurred after the first dose of trospium chloride. Angioedema associated with upper airway swelling may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, trospium chloride should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.
Trospium chloride should be administered with caution to patients with gastrointestinal obstructive disorders because of the risk of gastric retention . Trospium chloride, like other antimuscarinic agents, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony and myasthenia gravis.
In patients being treated for narrow-angle glaucoma, trospium chloride should only be used if the potential benefits outweigh the risks and in that circumstance only with careful monitoring .
Trospium chloride is associated with anticholinergic central nervous system (CNS) effects
. A variety of CNS anticholinergic effects have been reported, including dizziness, confusion, hallucinations and somnolence. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. …
Trospium side effects
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of trospium chloride was evaluated in controlled clinical trials in a total of 2975 patients, who were treated with trospium chloride (N=1673), placebo (N=1056) or active control medications (N=246). Of this total, 1181 patients participated in two, 12-week, U.S., efficacy and safety studies and a 9-month open-label extension. Of this total, 591 patients received trospium chloride 20 mg twice daily. In all controlled trials combined, 232 and 208 patients received treatment with trospium chloride for at least 24 and 52 weeks, respectively.
In all placebo-controlled trials combined, the incidence of serious adverse events was 2.9% among patients receiving trospium chloride 20 mg twice daily and 1.5% among patients receiving placebo. Table 1 lists adverse reactions from the combined 12-week U.S. safety and efficacy trials were reported by at least 1% of patients, and were reported more frequently in the trospium chloride group than in the placebo group.
The two most common adverse reactions reported by patients receiving trospium chloride 20 mg twice daily were dry mouth and constipation. …
Drug interactions
Concomitant use of trospium chloride and digoxin did not affect the pharmacokinetics of either drug .
Although demonstrated in a drug-drug interaction study not to affect the pharmacokinetics of digoxin, trospium chloride has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g., procainamide, pancuronium, morphine, vancomycin, and tenofovir). Coadministration of trospium chloride with these drugs may increase the serum concentration of trospium chloride and/or the coadministered drug due to competition for this elimination pathway. Careful patient monitoring is recommended in patients receiving such drugs .
The concomitant use of trospium chloride with other antimuscarinic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. Trospium chloride may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. …
About this medicine
Trospium chloride, USP is a quaternary ammonium compound with the chemical name of Spiro [8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1
R, 3
r, 5
S). The empirical formula of trospium chloride, USP is C
25H
30ClNO
3 and its molecular weight is 427.96 g/mol. The structural formula of trospium chloride, USP is represented below:
Trospium chloride, USP is a white or almost white, crystalline powder. It is very soluble in water, freely soluble in methanol, practically insoluble in methylene chloride.
Each Trospium Chloride Tablet, USP contains 20 mg of trospium chloride, USP, a muscarinic antagonist, for oral administration. Each tablet also contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, corn starch, povidone, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, titanium dioxide, polyethylene glycol 400, hypromellose, yellow iron oxide and red iron oxide.
How it works: Trospium chloride is a muscarinic antagonist. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID cdbb462c-c7a8-4b04-8abe-4de9b88591a0. Read the full official label on DailyMed.